lifestyle.microcapnews.com

Author: Lir Life Sciences Corp.

LIR Life Sciences Corp. Announces Agreement with Resilience BioSciences Inc.

April 20, 2026
LIR Life Sciences Commences Project Phase 2 Peptide Design Program with Neuland Laboratories

February 11, 2026
LIR Life Sciences Reports Positive Interim Preclinical Results from Comparative Animal Study of Novel CPP-Enabled Transdermal Delivery of GLP/GIP-Based Therapies

January 29, 2026
LIR Life Sciences Completes Design of Ex Vivo Animal Study to Evaluate Novel Transdermal Agents for Transport of Larger Therapeutic Molecules

January 23, 2026
LIR Life Sciences Launches Comparative Animal Study to Advance Transdermal Delivery of Second Generation GLP/GIP-based Obesity Therapies

January 15, 2026
LIR Life Engages Neuland Labs to Advance Development of Cell Penetrating Peptides for Transdermal GLP-1/GIP Platform

January 8, 2026
LIR Life Sciences Announces Appointment of Dr. Peter Singer as Scientific Advisor

December 21, 2025
LIR Life Sciences Files Provisional Patent Application for Needle-Free Delivery of GLP/GIP-Based Obesity Therapies

December 12, 2025
Lir Life Sciences Completes Design of a Comparative Animal Study Investigating Cell-Penetrating Peptide-Mediated Delivery of GLP/GIP-Based Obesity Therapies

December 11, 2025